| Characteristic . | . |
|---|---|
| Persistent/paroxysmal AF | 29/7 |
| Age (years) | 63 ± 9 |
| History of AF (months) | 52 (38–110) |
| Left atrial diameter (mm) | 48 ± 7 |
| LVEF (%) | 53 ± 15 |
| CHADS2 score | |
| 0 or 1 | 36% (13) |
| 2 or more | 64% (23) |
| Prior conventional ablation | 42% (15) |
| Number failing amiodarone | 61% (22) |
| Days since amiodarone discontinued | 365 (69–730) |
| Concomitant drug therapy | |
| ACEI/ARB | 58% (21) |
| β-Adrenoceptor antagonists | 67% (24) |
| Statins | 53% (19) |
| Comorbid conditions | |
| Hypertension | 86% (31) |
| Diabetes | 33% (12) |
| Prior stroke/TIA | 17% (6) |
| Coronary disease | 50% (18) |
| Hypercholesterolaemia | 86% (30) |
| Characteristic . | . |
|---|---|
| Persistent/paroxysmal AF | 29/7 |
| Age (years) | 63 ± 9 |
| History of AF (months) | 52 (38–110) |
| Left atrial diameter (mm) | 48 ± 7 |
| LVEF (%) | 53 ± 15 |
| CHADS2 score | |
| 0 or 1 | 36% (13) |
| 2 or more | 64% (23) |
| Prior conventional ablation | 42% (15) |
| Number failing amiodarone | 61% (22) |
| Days since amiodarone discontinued | 365 (69–730) |
| Concomitant drug therapy | |
| ACEI/ARB | 58% (21) |
| β-Adrenoceptor antagonists | 67% (24) |
| Statins | 53% (19) |
| Comorbid conditions | |
| Hypertension | 86% (31) |
| Diabetes | 33% (12) |
| Prior stroke/TIA | 17% (6) |
| Coronary disease | 50% (18) |
| Hypercholesterolaemia | 86% (30) |
Normally distributed variables are listed as mean ± standard deviation; non-normally distributed values are listed as median (interquartile range).
| Characteristic . | . |
|---|---|
| Persistent/paroxysmal AF | 29/7 |
| Age (years) | 63 ± 9 |
| History of AF (months) | 52 (38–110) |
| Left atrial diameter (mm) | 48 ± 7 |
| LVEF (%) | 53 ± 15 |
| CHADS2 score | |
| 0 or 1 | 36% (13) |
| 2 or more | 64% (23) |
| Prior conventional ablation | 42% (15) |
| Number failing amiodarone | 61% (22) |
| Days since amiodarone discontinued | 365 (69–730) |
| Concomitant drug therapy | |
| ACEI/ARB | 58% (21) |
| β-Adrenoceptor antagonists | 67% (24) |
| Statins | 53% (19) |
| Comorbid conditions | |
| Hypertension | 86% (31) |
| Diabetes | 33% (12) |
| Prior stroke/TIA | 17% (6) |
| Coronary disease | 50% (18) |
| Hypercholesterolaemia | 86% (30) |
| Characteristic . | . |
|---|---|
| Persistent/paroxysmal AF | 29/7 |
| Age (years) | 63 ± 9 |
| History of AF (months) | 52 (38–110) |
| Left atrial diameter (mm) | 48 ± 7 |
| LVEF (%) | 53 ± 15 |
| CHADS2 score | |
| 0 or 1 | 36% (13) |
| 2 or more | 64% (23) |
| Prior conventional ablation | 42% (15) |
| Number failing amiodarone | 61% (22) |
| Days since amiodarone discontinued | 365 (69–730) |
| Concomitant drug therapy | |
| ACEI/ARB | 58% (21) |
| β-Adrenoceptor antagonists | 67% (24) |
| Statins | 53% (19) |
| Comorbid conditions | |
| Hypertension | 86% (31) |
| Diabetes | 33% (12) |
| Prior stroke/TIA | 17% (6) |
| Coronary disease | 50% (18) |
| Hypercholesterolaemia | 86% (30) |
Normally distributed variables are listed as mean ± standard deviation; non-normally distributed values are listed as median (interquartile range).
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
